scholarly journals Therapeutic Targeting of Cancer Stem Cells via Modulation of the Renin-Angiotensin System

2019 ◽  
Vol 9 ◽  
Author(s):  
Imogen M. Roth ◽  
Agadha C. Wickremesekera ◽  
Susrutha K. Wickremesekera ◽  
Paul F. Davis ◽  
Swee T. Tan
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Renin Angiotensin System ◽  
Therapeutic Targeting ◽  
Angiotensin System ◽  
Renin Angiotensin

scholarly journals Glioblastoma Multiforme Cancer Stem Cells Express Components of the Renin–Angiotensin System

2016 ◽  
Vol 3 ◽  
Author(s):  
Amy Ruth Bradshaw ◽  
Agadha Crisantha Wickremesekera ◽  
Helen D. Brasch ◽  
Alice M. Chibnall ◽  
Paul F. Davis ◽  
...  
Keyword(s):  
Stem Cells ◽  
Glioblastoma Multiforme ◽  
Cancer Stem Cells ◽  
Renin Angiotensin System ◽  
Angiotensin System ◽  
Renin Angiotensin

scholarly journals Therapeutic Targeting of Cancer Stem Cells in Human Glioblastoma by Manipulating the Renin-Angiotensin System

Cells ◽  
2019 ◽  
Vol 8 (11) ◽  
pp. 1364 ◽  
Author(s):  
David Tan ◽  
Imogen Roth ◽  
Agadha Wickremesekera ◽  
Paul Davis ◽  
Andrew Kaye ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Embryonic Stem ◽  
Renin Angiotensin System ◽  
Adjuvant Chemoradiotherapy ◽  
Stem Cell Markers ◽  
The Novel ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
The Central Nervous System

Patients with glioblastoma (GB), a highly aggressive brain tumor, have a median survival of 14.6 months following neurosurgical resection and adjuvant chemoradiotherapy. Quiescent GB cancer stem cells (CSCs) invariably cause local recurrence. These GB CSCs can be identified by embryonic stem cell markers, express components of the renin-angiotensin system (RAS) and are associated with circulating CSCs. Despite the presence of circulating CSCs, GB patients rarely develop distant metastasis outside the central nervous system. This paper reviews the current literature on GB growth inhibition in relation to CSCs, circulating CSCs, the RAS and the novel therapeutic approach by repurposing drugs that target the RAS to improve overall symptom-free survival and maintain quality of life.

scholarly journals Cancer stem cells in liver metastasis from colon adenocarcinoma express components of the renin-angiotensin system

2019 ◽  
Vol 2019 ◽  
Author(s):  
Anantha Narayanan ◽  
Susrutha K. Wickremesekera ◽  
Bede Van Schaijik ◽  
Reginald W. Marsh ◽  
Helen D. Brasch ◽  
...  
Keyword(s):  
Stem Cells ◽  
Liver Metastasis ◽  
Cancer Stem Cells ◽  
Colon Adenocarcinoma ◽  
Renin Angiotensin System ◽  
Angiotensin System ◽  
Renin Angiotensin

scholarly journals Therapeutic Targeting of Cancer Stem Cells in Human Glioblastoma by Manipulating the Renin-angiotensin System

2019 ◽  
Author(s):  
David C.H. Tan ◽  
Imogen Roth ◽  
Agadha Wickremesekera ◽  
Paul F. Davis ◽  
Andrew H. Kaye ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Embryonic Stem ◽  
Renin Angiotensin System ◽  
Adjuvant Chemoradiotherapy ◽  
Stem Cell Markers ◽  
The Novel ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
The Central Nervous System

Patients with glioblastoma (GB), a highly aggressive brain tumor, have a median survival of 14.6 months following neurosurgical resection with adjuvant chemoradiotherapy. Quiescent GB cancer stem cells (CSCs) invariably cause local recurrence. These GB CSCs that can be identified by embryonic stem cell markers express components of the renin-angiotensin system and are associated with circulating CSCs. Despite the presence of circulating CSCs, GB rarely develops distant metastasis outside the central nervous system. This paper reviews the current literature on GB growth inhibition in relation to CSCs, circulating CSCs, the RAS and the novel therapeutic approach by repurposing drugs that target the renin-angiotensin system to improve overall symptom-free survival and maintain quality of life.

The Role of the Renin–Angiotensin System in the Cancer Stem Cell Niche

2021 ◽  
pp. 002215542110262
Author(s):  
Ethan J. Kilmister ◽  
Swee T. Tan
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Signaling Pathways ◽  
Renin Angiotensin System ◽  
Epidemiological Data ◽  
Malignant Cells ◽  
Angiotensin System ◽  
Renin Angiotensin

Cancer stem cells (CSCs) drive metastasis, treatment resistance, and tumor recurrence. CSCs reside within a niche, an anatomically distinct site within the tumor microenvironment (TME) that consists of malignant and non-malignant cells, including immune cells. The renin–angiotensin system (RAS), a critical regulator of stem cells and key developmental processes, plays a vital role in the TME. Non-malignant cells within the CSC niche and stem cell signaling pathways such as the Wnt, Hedgehog, and Notch pathways influence CSCs. Components of the RAS and cathepsins B and D that constitute bypass loops of the RAS are expressed on CSCs in many cancer types. There is extensive in vitro and in vivo evidence showing that RAS inhibition reduces tumor growth, cell proliferation, invasion, and metastasis. However, there is inconsistent epidemiological data on the effect of RAS inhibitors on cancer incidence and survival outcomes, attributed to different patient characteristics and methodologies used between studies. Further mechanistic studies are warranted to investigate the precise effects of the RAS on CSCs directly and/or the CSC niche. Targeting the RAS, its bypass loops, and convergent signaling pathways participating in the TME and other key stem cell pathways that regulate CSCs may be a novel approach to cancer treatment:

Sign in / Sign up

Export Citation Format

Share Document